Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

Now, a new study published in JAMA Network Open suggests that for people with obesity and type 2 diabetes, these drugs—known as GLP-1 receptor agonists —may also reduce the risk of death and lower the ...

A recent study revealed that weight loss drugs, GLP-1s, including Ozempic and Zepbound, may help in treating several chronic ...

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

A new study found that semaglutides like Ozempic are linked to a lower risk of Alzheimer's disease and dementia. Below, a neurologist explains the connection.

THEY’VE been hailed as miracle weight-loss jabs – but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called “skinny pens” may also ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Ozempic use is associated with a lowered risk for cognitive problems, researchers in a new study said. The findings, however, cannot be applied to users who do not have diabetes. The study ...

Ozempic linked to lower dementia rate in Oxford study After a year on the drug, patients had a 48% lower risk of dementia compared with those who’d taken sitagliptin.

Ozempic may lower dementia and nicotine dependence risk in people with type 2 diabetes. A recent study shows fewer cognitive deficits and lower smoking rates compared with other diabetes drugs.

Novo Nordisk A/S’s Ozempic was linked to lower rates of dementia and a range of other mental problems in a University of Oxford study that raises expectations about the diabetes drug’s ...